An interventional study of lipitor in Diabetes, sponsored by Johns Hopkins University. Terminated at 1 site in United States. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2017-09-13.
Sponsored by Johns Hopkins University · Not applicable, Interventional, and Diagnostic
Cholesterol-lowering drugs called statins improve the functioning of the endothelium, and help prevent heart disease. The investigators are testing whether statins improve endothelial function more in the arteries that have worse endothelium to begin with. One of the functions of the endothelium is to help control how blood vessels dilate (expand) or contract (narrow) in different situations. This affects how blood flows through those vessels. Magnetic resonance imaging (MRI) can be used to evaluate endothelial function in the arms and legs noninvasively.
Correct
Johns Hopkins University is the lead sponsor of 1,783 studies on the registry; 313 are open to participants now.
Of its 203 completed or terminated interventional studies of FDA-regulated products, 140 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
80 mg atorvastatin daily for 3 weeks
Drug: lipitor
80 mg everyday (QD) for 3 weeks
Also known as: atorvastatin
Mean Change in Low Density Lipoprotein (LDL)
Serum LDL, mg/dL (baseline LDL-follow-up LDL)
Time frame: Change from baseline to follow-up, up to 5 weeks
Change in Endothelial Function as Measured on MRI in the Arms
Time frame: chance from baseline to end of study, up to 5 weeks
Change in Endothelial Function as Measured on MRI in the Legs
Time frame: chance from baseline to end of study, up to 5 weeks
| Milestone | High-Dose Statin |
|---|---|
| Started | 16 |
| Completed | 10 |
| Not completed | 6 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Follow-up ldl measurement not collected | 3 |
Serum LDL, mg/dL (baseline LDL-follow-up LDL)
| mg/dL | High-Dose Statin |
|---|---|
| Mean Change in Low Density Lipoprotein (LDL) | 75.54 ± 12.98 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| High-Dose Statin | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Age, Customized(Participants) | High-Dose Statin |
|---|---|
| >=40, <=90, years | 16 |
| Sex: Female, Male(Participants) | High-Dose Statin |
|---|---|
| Female | 6 |
| Male | 10 |
| Region of Enrollment(Participants) | High-Dose Statin |
|---|---|
| United States | 16 |
This study is terminated, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johns Hopkins University